Rationale and Trial Design of DAWNA‐FES Trial: Single‐Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [18F]FES PET/CT in Patients With HR+/HER2− Advanced Breast Cancer.
Saved in:
| Title: | Rationale and Trial Design of DAWNA‐FES Trial: Single‐Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [18F]FES PET/CT in Patients With HR+/HER2− Advanced Breast Cancer. |
|---|---|
| Authors: | Yao, Ru1 (AUTHOR), Qu, Yang1 (AUTHOR), Hao, Zhixin2 (AUTHOR), Xu, Ying (AUTHOR), Zhang, Jiahui1 (AUTHOR), Lian, Jie1 (AUTHOR), Gao, Lu1 (AUTHOR), Shen, Songjie1 (AUTHOR), Mao, Feng1 (AUTHOR), Pan, Bo1 (AUTHOR) panbo@pumch.cn, Sun, Qiang1 (AUTHOR), Huo, Li2 (AUTHOR) huoli@pumch.cn, Zhou, Yidong1 (AUTHOR) zhouyd@pumch.cn |
| Source: | Cancer Innovation. Jun2026, Vol. 5 Issue 3, p1-8. 8p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
